Source: Insider Media

Abstract Securities: Green light for second phase of biotech development at South Cambridge Science Centre

Abstract (Mid-Tech) has obtained detailed planning consent for the second phase of its development at South Cambridge Science Centre.

Read full article »
Abstract Securities's Competitors | Abstract Securities's News | Abstract Securities's Financials
Stay up-to-date with the latest news on Abstract Securities
Est. Annual Revenue
$5.0-25M
Est. Employees
25-100
Mark Glatman's photo - CEO of Abstract Securities

CEO

Mark Glatman

CEO Approval Rating

74/100

Read more
Stay up-to-date with the latest news on Abstract Securities